88IV - PR Newswire Asia's news - Medical/Pharmaceuticals


Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies PRINCETON, N.J. and SUZHOU, China , Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology Leverages fermentation know-how developed through MIWON to expand beyond general-purpose amino acids into high-value pharmaceutical materials Acquires Germany-based AMINO GmbH, gaining purification ... 2026-09-09T Biotechnology Food/Beverages Medical/Pharmaceuticals
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Abbott and Sengkang General Hospital expand partnership to advance early detection of muscle loss and support healthy aging The expanded three-year collaboration will integrate muscle health screenings into hospital and community settings, train healthcare professionals, and increase public education Since launching in 2023, ... 2026-09-09T Health Care/Hospital Medical/Pharmaceuticals
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize Joint research team modeled a 12,635-atom protein, the largest-known to be simulated using quantum computers. ... 2026-09-09T Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals Peripherals
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026 Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Metabolon Verus™ Metabolomics Profiling Kit Now Available to Order A successful multi-site ring trial and early access program demonstrate the reproducibility, scalability, and biological insight of the Metabolon Verus™ Metabolomics Profiling Kit across laboratories ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo NEW YORK and SUZHOU, China , Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Medical/Pharmaceuticals